Genomic Insights into High-Grade Infarct-Associated Bone Sarcomas.

[1]  M. Bourgeau,et al.  Superficial dedifferentiated liposarcoma: A clinicopathologic study. , 2024, Human pathology.

[2]  J. Hench,et al.  Recent advances in molecular profiling of bone and soft tissue tumors , 2024, Skeletal radiology.

[3]  C. Iacobuzio-Donahue,et al.  Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma , 2023, Cancer research.

[4]  C. Antonescu,et al.  Distinct genomic landscapes in radiation‐associated angiosarcoma compared with other radiation‐associated sarcoma histologies , 2023, The Journal of pathology.

[5]  Lujun Shen,et al.  Genomic Profiling of Radiation-Induced Sarcomas Reveals the Immunologic Characteristics and Its Response to Immune Checkpoint Blockade , 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  M. Hameed,et al.  Giant-cell-poor giant cell tumor of bone: report of two cases and literature review , 2023, Skeletal Radiology.

[7]  M. Rubin,et al.  Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma , 2023, EMBO molecular medicine.

[8]  Jan Krakowiak,et al.  Bone Infarcts and Tumorigenesis—Is There a Connection? A Mini-Mapping Review , 2022, International journal of environmental research and public health.

[9]  S. Fröhling,et al.  Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD) , 2022, npj Precision Oncology.

[10]  D. Donati,et al.  Bone Infarct-Associated Osteosarcoma: Epidemiologic and Survival Trends , 2022, Oncology Research and Treatment.

[11]  S. Sleijfer,et al.  Bone sarcomas: ESMO-EURACAN-GENTURIS-ERNPaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Benjamin J. Raphael,et al.  Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time , 2021, bioRxiv.

[13]  A. Luebke,et al.  H3F3A‐mutated giant cell tumour of bone without giant cells—clinical presentation, radiology and histology of three cases , 2021, Histopathology.

[14]  Lu Xie,et al.  The Clinical Implications of Tumor Mutational Burden in Osteosarcoma , 2021, Frontiers in Oncology.

[15]  David C. Jones,et al.  Drivers underpinning the malignant transformation of giant cell tumour of bone , 2020, medRxiv.

[16]  S. Fröhling,et al.  The landscape of chromothripsis across adult cancer types , 2020, Nature Communications.

[17]  Safdar N. Khan,et al.  Malignant fibrous histiocytoma of bone: A survival analysis from the National Cancer Database , 2020, Journal of surgical oncology.

[18]  Marilyn M. Li,et al.  Copy number assessment in the genomic analysis of CNS neoplasia: An evidence-based review from the cancer genomics consortium (CGC) working group on primary CNS tumors. , 2020, Cancer genetics.

[19]  Vanessa L. Horner,et al.  Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consort , 2019, Genetics in Medicine.

[20]  C. Antonescu,et al.  Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone , 2018, The Journal of pathology.

[21]  Hong Yang,et al.  Consistent Amplification of FRS2 and MDM2 in Low-grade Osteosarcoma: A Genetic Study of 22 Cases With Clinicopathologic Analysis , 2018, The American journal of surgical pathology.

[22]  Ken Chen,et al.  Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing , 2018, Nature Genetics.

[23]  Michael C. Heinold,et al.  The landscape of genomic alterations across childhood cancers , 2018, Nature.

[24]  D. Frishman,et al.  Genome‐wide analysis of somatic copy number alterations and chromosomal breakages in osteosarcoma , 2017, International journal of cancer.

[25]  David T. W. Jones,et al.  Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases , 2017, Clinical Sarcoma Research.

[26]  E. Bruner,et al.  Myxofibrosarcoma: First report of myxofibrosarcoma of bone arising at a bone infarct , 2017, Skeletal Radiology.

[27]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[28]  R. Benjamin,et al.  Chemotherapy for Bone Sarcoma in Adults. , 2016, Journal of oncology practice.

[29]  A. Cleton-Jansen,et al.  Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma , 2015, The American journal of surgical pathology.

[30]  A. Montag,et al.  Infarct-Associated Bone Sarcomas: Multimodality Imaging Findings. , 2015, AJR. American journal of roentgenology.

[31]  A. B. Hassan,et al.  Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast‐rich mimics , 2015, The journal of pathology. Clinical research.

[32]  Li Ding,et al.  Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. , 2014, Cell reports.

[33]  L. Wood,et al.  Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas , 2014, Genes, chromosomes & cancer.

[34]  M. Stratton,et al.  Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone , 2013, Nature Genetics.

[35]  A. Vincent-Salomon,et al.  Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. , 2012, Cancer research.

[36]  G. Mills,et al.  Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.

[37]  M. Rosemann,et al.  Secondary Radiation-Induced Bone Tumours Demonstrate a High Degree of Genomic Instability Predictive of a Poor Prognosis , 2012, Current genomics.

[38]  Z. Szallasi,et al.  Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. , 2012, Cancer discovery.

[39]  Y. Washimi,et al.  A p53 gene mutation in malignant fibrous histiocytoma associated with bone infarction. , 2011, The Tohoku journal of experimental medicine.

[40]  S. Knuutila,et al.  Array comparative genomic hybridization reveals frequent alterations of G1/S checkpoint genes in undifferentiated pleomorphic sarcoma of bone , 2011, Genes, chromosomes & cancer.

[41]  D. Jeon,et al.  MFH of Bone and Osteosarcoma Show Similar Survival and Chemosensitivity , 2011, Clinical orthopaedics and related research.

[42]  A. Cleton-Jansen,et al.  Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2 , 2009, The Journal of pathology.

[43]  C. H. Bush,et al.  Infarct-associated Bone Sarcomas , 2009, Clinical orthopaedics and related research.

[44]  N. Athanasou,et al.  Leiomyosarcoma of Bone Arising in Association with a Bone Infarct , 2002, Sarcoma.

[45]  M. van Glabbeke,et al.  Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European Osteosarcoma Intergroup study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  G. Hermann,et al.  Angiosarcomas associated with bone infarcts , 1998, Skeletal Radiology.

[47]  S. Ferrari,et al.  Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  F. Torres,et al.  Bone infarct‐associated osteosarcoma , 1992, Cancer.

[49]  J. Furey,et al.  Fibrosarcoma arising at the site of bone infarcts. A report of 2 cases. , 1960, The Journal of bone and joint surgery. American volume.